Kiora Pharmaceuticals, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Kiora is a clinical-stage specialty pharmaceutical company developing ophthalmic therapies. The report covers the three and six months ended June 30, 2022, filed August 12, 2022. The company has not generated significant revenue or achieved profitability.
- Lead programs: KIO-301 for inherited and age-related retinal degeneration, KIO-101 for ocular inflammation associated with rheumatoid arthritis, and KIO-201 for persistent corneal epithelial defects and surgical recovery.
- Management expected to initiate a Phase 1b trial for KIO-301 in the third quarter of 2022, a Phase 2 trial for KIO-101 in the second half of 2022, and report KIO-201 Phase 2 topline results in the first quarter of 2023.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | No significant revenue | No significant revenue |
| Operating expenses | $2.402 million | $5.971 million |
| Net loss | $2.401 million | $5.966 million |
| Net loss per share | $0.18 | $0.46 |
| Net cash used in operating activities | Not provided | $5.331 million |
- Six-month general and administrative expense was $3.467 million, up $0.861 million year over year, primarily from higher consulting, audit, legal, travel and office costs.
- Six-month research and development expense was $1.275 million, down $1.445 million, primarily due to lower KIO-101 and KIO-201 development and personnel costs.
- Six-month operating expenses included $0.963 million of executive severance and a $0.267 million increase in the fair value of contingent consideration.
- Cash, cash equivalents and restricted cash totaled $2.477 million at June 30, 2022, compared with $7.900 million at December 31, 2021. Unrestricted cash was $2.428 million.
- Total liabilities were $6.701 million, including $3.316 million of contingent consideration. The filing does not identify outstanding conventional borrowings or debt principal.
- Stockholders’ equity declined to $8.762 million from $14.579 million at December 31, 2021.
Material Changes Versus the Prior Comparable Period
- Second-quarter net loss improved by $0.142 million to $2.401 million, as lower research and development expense and the absence of the prior-year Paycheck Protection Program forgiveness gain were more than offset by higher general and administrative expense.
- Six-month net loss increased by $1.412 million to $5.966 million. The increase reflected executive severance, higher general and administrative expense, and the unfavorable change in contingent consideration fair value.
- Operating cash use decreased modestly from $5.486 million to $5.331 million, but the company had no financing cash inflows in the first six months of 2022 compared with $8.039 million in the prior-year period.
- On June 18, 2022, the company issued 403,461 common shares previously held back in connection with the Panoptes acquisition.
Guidance, Outlook, Risks and Unusual Items
- Management stated that cash on hand at June 30, 2022, together with $5.297 million of net proceeds from a subsequent offering, was expected to fund planned operations through March 2023. Additional capital will be required to continue development.
- The July 26, 2022 public offering issued 23,695,697 common shares, 1,280 Series E convertible preferred shares convertible into up to 6.4 million common shares, and Class A and Class B warrants for up to 30,095,697 common shares each. The offering creates substantial potential dilution.
- Management concluded that recurring losses and negative cash flows create substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no going-concern adjustments.
- Nasdaq notified the company that its common stock did not meet the $1.00 minimum bid-price requirement. The initial compliance period ran through August 22, 2022; management stated that a reverse stock split could be considered.
- Disclosure controls and procedures were deemed ineffective as of June 30, 2022 because of previously identified material weaknesses in internal control over financial reporting. Remediation was underway but not complete.
- In July 2022, the company identified an apparent payroll irregularity involving approximately $0.120 million paid to unauthorized recipients. An independent firm was retained to investigate and review related controls.
- Key risks include clinical and regulatory failure, inability to obtain additional financing, dilution, contingent milestone obligations, intellectual-property and licensing risks, COVID-19-related disruption, Nasdaq delisting, and incomplete remediation of internal-control weaknesses.
Facts Investors Should Verify
- Actual cash runway after the July 2022 offering and the timing and terms of any additional financing.
- Progress and results of the planned KIO-301, KIO-101 and KIO-201 clinical programs.
- Whether the company regained compliance with Nasdaq’s minimum bid-price requirement or completed a reverse stock split.
- Investigation findings and remediation status related to the payroll irregularity and material weaknesses in internal controls.
- Potential dilution from the July 2022 preferred shares, warrants, options and other reserved securities.
- Achievement probability and payment timing for up to $18.799 million of acquisition-related contingent consideration.